Literature DB >> 11328302

Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation.

G Socié1, J Y Mary, H Esperou, D V Robert, S Aractingi, P Ribaud, A Devergie, M E Toubert, P Boudou, B Cathelinau, E Gluckman, P Vexiau.   

Abstract

Increasing numbers of patients are surviving after allogeneic haematopoietic stem cell transplantation (SCT). Among these patients, a number of late complications have been described but few data on the risk factors of these long-term effects of SCT are available. We report the analysis on 105 adult patients, surviving free of haematological disease at a median time of 15 months after SCT. At the time of screening, 52% had returned to work, general health status was normal in 67% and 47% were sexually active. Female patient gender odds ratio (OR) 2.9 (P = 0.01) and age > 25 years (OR = 3.2, P = 0.02) were associated with non-return to work. Decreased general status was associated with chronic graft-versus-host disease (GvHD) (OR = 3.2, P = 0.009) and irradiation (OR = 3.6, P = 0.004). Sexual inactivity was associated with younger age (OR = 7.0, P = 0.0002) and chronic GvHD (OR = 3.3, P = 0.006). Risk factors for altered pulmonary function tests included previous smoking habits, irradiation and chronic GvHD. Obstructive lung disease was associated with a previous history of asthma. Sicca syndrome and conjunctivitis were increased in patients with previous acute GvHD and cataracts were less frequent in patients with aplastic anaemia. Persistent impaired hair re-growth was less frequent in patients who received irradiation (OR = 0.18, P = 0.002) but increased in patients with previous acute GvHD (OR = 5.3, P = 0.007). Microalbuminuria was more frequent in irradiated patients (OR = 9.4, P = 0.05). Raised cholesterol was associated with age (OR = 20.8, P < 0.001), previous acute GvHD (OR = 4.7, P = 0.03), steroid use (OR = 6.3, P = 0.001) and familial hypercholesterolaemia (OR = 4.4, P = 0.04). Decreased bone density was associated with chronic GvHD (OR = 3.9, P = 0.001). Thus, using routine tests in adult patients we were able to detect significant numbers of-non-symptomatic complications enabling early treatment.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11328302     DOI: 10.1046/j.1365-2141.2001.02678.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  18 in total

1.  Hyperlipidemia and statin use after allogeneic hematopoietic stem cell transplantation.

Authors:  Bradley W Blaser; Haesook T Kim; Edwin P Alyea; Vincent T Ho; Corey Cutler; Philippe Armand; John Koreth; Joseph H Antin; Jorge Plutzky; Robert J Soiffer
Journal:  Biol Blood Marrow Transplant       Date:  2011-08-11       Impact factor: 5.742

Review 2.  Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities.

Authors:  Rajshekhar Chakraborty; Surbhi Sidana; Gunjan L Shah; Michael Scordo; Betty K Hamilton; Navneet S Majhail
Journal:  Biol Blood Marrow Transplant       Date:  2018-11-28       Impact factor: 5.742

3.  Relationship between neurocognitive functioning and medication management ability over the first 6 months following allogeneic stem cell transplantation.

Authors:  S Mayo; H A Messner; S B Rourke; D Howell; J C Victor; J Kuruvilla; J H Lipton; V Gupta; D D Kim; C Piescic; D Breen; A Lambie; D Loach; F V Michelis; N Alam; J Uhm; L McGillis; K Metcalfe
Journal:  Bone Marrow Transplant       Date:  2016-02-29       Impact factor: 5.483

4.  Occupational status among adult survivors following allo-SCT.

Authors:  J Winterling; E Johansson; A Wennman-Larsen; L-M Petersson; P Ljungman; K Alexanderson
Journal:  Bone Marrow Transplant       Date:  2014-03-10       Impact factor: 5.483

Review 5.  Gender aspects of treatment and drug related toxicity in medical oncology.

Authors:  Christine Marosi
Journal:  Wien Med Wochenschr       Date:  2006-10

6.  Impaired physiological function and health-related QOL in patients before hematopoietic stem-cell transplantation.

Authors:  Shinichiro Morishita; Katsuji Kaida; Kazuhiro Ikegame; Satoshi Yoshihara; Kyoko Taniguchi; Masaya Okada; Norihiko Kodama; Hiroyasu Ogawa; Kazuhisa Domen
Journal:  Support Care Cancer       Date:  2011-04-09       Impact factor: 3.603

Review 7.  National Institutes of Health Hematopoietic Cell Transplantation Late Effects Initiative: The Patient-Centered Outcomes Working Group Report.

Authors:  Margaret Bevans; Areej El-Jawahri; D Kathryn Tierney; Lori Wiener; William A Wood; Flora Hoodin; Erin E Kent; Paul B Jacobsen; Stephanie J Lee; Matthew M Hsieh; Ellen M Denzen; Karen L Syrjala
Journal:  Biol Blood Marrow Transplant       Date:  2016-09-19       Impact factor: 5.742

8.  Prospective predictors of return to work in the 5 years after hematopoietic cell transplantation.

Authors:  Anne C Kirchhoff; Wendy Leisenring; Karen L Syrjala
Journal:  J Cancer Surviv       Date:  2010-03       Impact factor: 4.442

9.  Cardiac effects of chronic graft-versus-host disease after stem cell transplantation.

Authors:  Ali Dogan; Orhan Dogdu; Ibrahim Ozdogru; Mikail Yarlioglues; Nihat Kalay; Mehmet Tugrul Inanc; Idris Ardic; Ahmet Celik; Leylagul Kaynar; Fatih Kurnaz; Namik Kemal Eryol; Mehmet Gungor Kaya
Journal:  Tex Heart Inst J       Date:  2013

10.  The effect of smoking on allogeneic transplant outcomes.

Authors:  David I Marks; Karen Ballen; Brent R Logan; Zhiwei Wang; Kathleen A Sobocinski; Andrea Bacigalupo; Linda J Burns; Vikas Gupta; Vincent Ho; Philip L McCarthy; Olle Ringdén; Harry C Schouten; Matthew Seftel; J Douglas Rizzo
Journal:  Biol Blood Marrow Transplant       Date:  2009-08-03       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.